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ABSTRACT
In the present review, organizational and activational hormonal effects are proposed to
be dysfunctional in schizophrenia and psychosis. Specifically, organizational effects are
held responsible for the long-lasting anatomical and functional changes in brain
development associated with the disease. Later in life, activational effects may be
superimposed and may interact with the earlier induced biological vulnerabilities,
eventually triggering the first psychotic episode in schizophrenia. In parallel, it is known
that schizophrenia follows a different course in male and female patients and that the
first psychotic episode frequently occurs shortly before or during puberty. The different
course of schizophrenia in male and female patients seems to be related to digressions
in hormonal secretion between the genders. Further the excessive change of hormonal
secretion during puberty suggests a relationship between hormonal secretion and the
development of schizophrenia, possibly mediated by epigenetic regulation of
neuroendocrine systems. We discuss the Hypothalamic-Pituitary-Gonadal (HPG), the
Hypothalamic-Pituitary-Adrenal (HPA) and the Somatotropic axes and further present
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evidence for positive treatment effects in schizophrenia by hormonal agents. We
conclude that organizational as well as activational effects of hormones may attribute to
the development of schizophrenia. Research on hormonal factors in schizophrenia might
therefore enhance the general understanding of the disease in regard to its neurobiology
and treatment options.
Keywords: Schizophrenia; psychosis; hormones; HPG axis; HPA axis; somatotrophic axis.
1. BACKGROUND
The Hypothalamic-Pituitary-Gonadal (HPG), the Hypothalamic-Pituitary-Adrenal (HPA) and
the Somatotrophic axes are important structures maintaining hormonal secretion in humans
[1]. The effects of hormonal secretion may be characterized as being organizational or
activational. For instance, sex specific characteristics of the human body and brain, known to
be programmed during gestation are the consequence of organizational as well as
activational processes of hormones secreted by these axes [2]. In general, organizational
processes reflect permanent anatomical and functional changes as a result of hormonal
secretion during brain development. Organizational effects are exemplified by digressions in
the size and shape of specific hypothalamic structures in men and women, which may be
caused by sex-associated hormonal activity in brain development [1]. In contrast, activational
processes reflect temporary changes in peripheral and neural processes together with
analogous fluctuations in hormonal and cognitive functions. Such short lasting changes are
often associated with the time of day, day of the month, season, as well as age. Depending
on different hormonal secretion and hormonal effects in men and women, activational effects
have also been found to be gender-specific [2].
Organizational and activational processes may also interact. For instance, aggressive
behavior in boys may result from the temporal action of testosterone, which is superimposed
on its permanent effect on male brain development. Thus, hormones may incidentally be the
cause of abnormal brain development, which may be accompanied with distinct direct effects
of hormones later in life. In addition, hormone-induced sex-associated differences in
cognitive functions are for instance, reflected by the different course in development of
schizophrenia in males and females.
The onset of the first signs of schizophrenia and psychosis are frequently reported during
puberty, and in 80% of the cases of schizophrenia, the first psychotic episode occurs during
the reproductive age [3]. Male schizophrenia patients often experience the first psychotic
episode in their early twenties, whereas women develop the first episode during their late
twenties [4,5]. Further, there is an increase of schizophrenia-like symptoms after
menopause, again an episode in life when strong hormonal changes are present [6,7,8].
Since body and brain undergo gender specific hormonal changes throughout life, hormonal
factors may be an underlying cause of the different course of schizophrenia in males and
females [9]. Indeed, several studies concluded that it is likely that gender differences during
the course of schizophrenia are dependent upon the secretion of sex hormones [10].
Moreover, in some cases psychosis can be completely halted by means of interfering with
hormonal factors and thus hormones are frequently held responsible for the exacerbation of
psychotic symptoms and might therefore be a causal factor for the development of the
disease [11,12]. Thus, altered hormonal secretion and the associated organizational and
activational effects may lead to abnormal cognitive development in schizophrenic patients. In
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line with this notion is the evidence that baseline hormone levels and number of receptors
are deviant in an early phase of schizophrenia [4,13]. The involvement of organizational and
activational effects of hormones in schizophrenia and psychosis has already been
hypothesized in an earlier study by Seeman and Lang [6]. However, in this study,
organizational and activational effects in schizophrenia were only discussed in relation to
estrogen and gender differences.
Schizophrenia has been classified by the Diagnostic and Statistical Manual of Mental
Disorders-IV (DSM-IV) into the schizophrenia subtypes paranoid, disorganized, catatonic,
undifferentiated and residual type. The subtypes have been removed in the new DSM-5
because of the limited diagnostic stability, low reliability and poor validity, according to the
American Psychiatric Association (APA). As these subtypes had limited use in biological
validation studies [14] and are dropped in DSM-5 it seems useless to search for hormonal
abnormalities that are specific for these schizophrenia subtypes.
In contrast, attempts have been made to define subgroups of schizophrenia exclusively
based on molecular profiles as well as on abnormalities in growth factors and hormones
(e.g. follicle stimulating hormones, cortisol, growth hormones etc). It has been reported that
schizophrenia patients can be divided into subgroups based on specific molecular and
hormonal patterns. Specifically, two distinct subgroups were identified, one group showing
predominant changes in immune molecules such as migration inhibitory factor (MIF),
interleukin (IL)-8, IL-ira, IL-18 and IL-16. In contrast, the other group showed more changes
in growth factors and hormones such as prolactin, resistin, testosterone, insulin, platelet-
derived growth factor, leptin and angiotensinogen. There was no association of patients in
either group with diagnostic subtypes of schizophrenia [15]. Although research in this area is
still in an early phase, this approach seems to be very promising.
In the present review we will address the organizational and activational effects of
hormones, including anatomical alterations of the pituitary and hippocampus, in
schizophrenia and associated psychosis. As there is no evidence of specific associations
between hormonal factors and subtypes of schizophrenia and these subtypes even have
been removed from DSM-5 we will not address specific diagnostic subtypes. Although
studies on new diagnostic subtypes are warranted, current evidence indicate that hormonal
abnormalities may be present in all forms of schizophrenia, likely at a different extent and
with specific profiles [15].
The search strategy was based on results of the key terms "schizophrenia, psychosis,
hormones,Hypothalamus-Pituitary-Gonadal, Hypothalamus-Pituitary-Adrenal, Somatotrophic
axes" on PubMed.com, including only articles in English language.
2. PITUITARY VOLUME
The size of the pituitary gland, which is involved in hormonal regulation and secretion, is
found to be increased in medicated schizophrenic patients [16]. Improvement in overall
psychotic symptoms in response to medication has also been found to be associated with
pituitary volume. Patients at the 25th percentile of pituitary volume (small pituitary volume)
are approximately three times more likely to respond to medication than patients at the 75th
percentile (large pituitary volume) [17]. In addition to altered pituitary volume there is
evidence of basal pituitary-adrenal overactivity, as indicated by higher plasma levels of
adrenocorticotropic hormone (ACTH) and cortisol (CORT) in patients during first psychosis
and in drug naïve diagnosed schizophrenic patients [18]. Thus, even after controlling for the
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effects of medication, pituitary volume and function seems to be abnormal in schizophrenia
and acute psychosis.
Other studies indicate that pituitary volume is increased by 10% in schizophrenic patients
during their first psychotic episode. However, in established schizophrenia (a duration of at
least 5 years) a reduction in pituitary volume of 17% is seen [19]. The authors assume that
an increased biological susceptibility to daily life stress or an increased amount of stressors
during the first psychotic episode may cause relatively direct alterations in neurochemical
factors leading to an increased pituitary size. After several years of chronic hyperactivation
of the HPA axis, long term changes such as gluccocorticoid (GC) resistance or sensitization
may ultimately lead to a decrease in pituitary volume [19]. Remarkably, also in non-affected
relatives of schizophrenic patients pituitary volume was found to be larger than that of
controls [20].
As the pituitary gland is almost exclusively involved in hormonal secretion and control, the
observed alterations of pituitary volume in medicated and drug-naïve schizophrenic patients
are likely related to disturbed neurochemical mechanisms of the HPA axis. In addition, the
observed increased pituitary volume in first degree relatives of schizophrenic patients may
point to a genetic predisposition mediating organizational effects of stress hormones on
brain dysfunction.
3. HPG-AXIS
Puberty is a period in human life wherein hormonal activity and its effects are changing and
permanent long-lasting changes in endocrinological variables and brain anatomy are
established. During puberty, an increased activation of the HPG axis is observed [21]. The
HPG axis is mainly involved in the secretion of the gonadotropin releasing hormone (GnRH),
luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone (T) and estrogen
(E) [1].
In puberty the brain is still in a developmental phase, which is likely influenced by hormonal
changes. Abnormal organizational processes during puberty may contribute to the biological
predisposition for schizophrenia. In addition, subsequent activational effects of gonadal
hormones may trigger the occurrence of psychosis.
3.1 Organizational Effects of Gonadal Hormones
High estrogen (E) levels have often been discussed to be a protective factor in
schizophrenia, mainly due to the generally lower prevalence of the disease in females. This
hypothesis has been discussed as the “estrogen protection hypothesis of schizophrenia”
[22,23]. It is also known that in both genders, E is capable of inducing neuronal regeneration
and suppressing oxidative stress or glutamatergic cell death [24]. In addition, the protective
effect of E is likely mediated via neurotransmitter interactions. E has effects on the
dopaminergic system by reducing the amount of D2-receptors and DAT transporters. Thus,
E seems to have antagonistic effects on dopamine comparable to the effects of
antipsychotics [25].
To investigate whether E could be a causal factor of schizophrenia, early assessment would
be necessary. However, assessment of E levels early in life, especially in fetuses is
complicated because it could danger the unborn child as well as the mother. Therefore, a
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retrospective assessment has been chosen in a study by Procopio, et al. [26]. As the ratio of
the length of the index finger to body height seems a valid measure of E concentration in the
child during pregnancy, this method was applied [26]. The sample consisted of 119 subjects
(27 male controls, 35 male patients, 32 female controls and 25 female patients) between 18
and 65 years, all patients fulfilling ICD-10 criteria for schizophrenia. The results indicated
that in female schizophrenia patients a reduced index finger to body height ratio is present.
The authors conclude that a relative high concentration of maternal E during pregnancy can
probably protect against traumas in utero or at least could limit the damage, while a lower
than average concentration of estrogens in utero and/or adult life may be less protective
[26].
It is plausible that genetic predispositions may contribute to decreased E concentrations in
schizophrenia. In a recent study, the E receptor alpha (ESR1) gene and cortical ESR1
mRNA have been shown to be associated to schizophrenia in case-control genetic
association analysis of postmortem brain tissue. Genetic polymorphisms in E specific genes
were more frequently observed in schizophrenics of broad ethnic origin compared to
controls. Further, 18 ESR1 splice variants and decreased frequencies of the wild-type ESR1
mRNA were detected in schizophrenia [27]. Thus, the variation in the ESR1 gene seems
associated with schizophrenia and the mechanism of this association may involve alternative
gene regulation and transcript processing [27]. In woman E may mediate the underlying
neurochemical and neuropathological abnormalities in schizophrenia and might therefore
also be effective in treating the symptoms of schizophrenia [22,23]. Hormonal treatment will
be discussed in a later section.
Although it is not clear whether protective effects of E are present in men, there is evidence
that other gonadal hormones such as testosterone (T) may be involved in the etiology of
schizophrenia in men. This notion is supported by a finding of a study in which male
schizophrenic patients (N=54) were assigned to groups with predominant negative and
nonpredominant negative symptoms, measured by the Positive and Negative Syndrome
Scale (PANSS) [28]. It was found that basal plasma levels of T and free T in schizophrenic
male patients with predominant and nonpredominant negative symptoms were significantly
lower than those in age matched normal controls. Moreover, plasma levels of FSH and LH in
patients with predominant negative symptoms but not in the patients with nonpredominant
negative symptoms were found to be significantly lower than in normal controls [28] and a
significant inverse correlation was found between the negative symptom scores of the
PANSS and plasma levels of free T and T in the subjects with predominant negative
symptoms [28]. In a more recent study, decreased levels of active T were found in
antipsychotic naive, newly diagnosed schizophrenic patients (N =33) in comparison to a well
(for age, sex, body mass index, socioeconomic status and smoking) matched control group
(N=33) [29]. In another quite recent study involving 21 male adolescents suffering from
prodromal symptoms associated with schizophrenia and 21 non-clinical male controls T
levels were determined in saliva. T levels appeared to be significantly lower in adolescents
with prodromal symptoms than in non-clinical controls [30]. The observation of low levels of
T before the onset of full blown schizophrenia is in line with the hypothesis of abnormal
organizational effects of hormones in schizophrenia.
The cited studies suggest a lower baseline level of gonadal hormones in schizophrenic
patients and even in patients at high risk to develop schizophrenia. The evidence indicates
that in adolescence and adulthood, male and female schizophrenic patient’s exhibit reduced
levels of respectively T and E while reduced levels of E may already observable in female
patients before birth. Although these findings do not proof a direct (causal) relationship
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between gonadal hormones and the development of schizophrenia, the observation of
subnormal hormonal levels in unmedicated patients and patients at high risk to develop
schizophrenia suggests that low levels of gonadal hormones may attribute to the
development of the disease.
3.2 Activational Effects of Gonadal Hormones
There are indications for the existence of an activational relationship between E and
schizophrenia superimposed on the organizational effects. The role of activational effects of
E in the onset of psychosis in schizophrenia has been hypothesized and discussed in earlier
studies (e.g. [6]). Further, changes in hormonal factors might contribute to the exacerbation
or improvement of psychotic symptoms in general [22,31]. It has also been shown that the
high-estrogen luteal phase is associated with significant improvements in psychopathology
and functioning in schizophrenic women compared to the low-estrogen follicular phase
[22,23]. More evidence of an activational effect of E in schizophrenia comes from life-cycle
studies in females. A 20-fold increased risk of suffering a first episode or relapse of psychotic
symptoms during the postpartum period of pregnancy was observed when E levels fell
dramatically. Further, chronic psychoses may improve during periods in pregnancy when E
levels are very high [22,23]. Psychotic women were also found to be more likely to be
admitted to a mental institution during a low E phase of their menstrual cycle in comparison
to controls [32]. Thus, lower E levels in schizophrenia seem associated with an increased
risk of psychotic symptoms. Additionally to the early onset psychosis which often starts
around the late 20´s, the onset of psychosis is often seen in postmenopausal women and
appears also associated with fluctuations in E during menopause [6,7,8].
It is not clear whether activational effects of E are present in men, although recent studies
showed that E might play a role in male schizophrenia as it might be of value as adjunctive
treatment [23]. With respect to T levels, it has been shown that these might be negatively
correlated with the negative symptomatology in subgroups of schizophrenia, as lower T
levels have been observed in a negative-symptom–dominant schizophrenic group compared
to a positive-symptom-dominant group of male schizophrenic patients. Unfortunately, only a
relative small group of schizophrenic patients were investigated (N=10). Still, similar results
were observed in larger samples in earlier studies, also discussed by [33]. No differences
were found for other hormones like estradiol and prolactine [33,34]. However, research on
activational effects of T in schizophrenia is scarce.
Taken together, the available evidence suggests that at the HPG axis activational effects
may be present in schizophrenia. This notion is based on the observed relationship of E and
T fluctuations with psychopathology in schizophrenia, low hormonal levels corresponding
with high symptomatology.
4. HPA-AXIS
The HPA axis is a major part of the neuroendocrine system, controlling mood and emotions.
In general, a disturbance of the HPA axis is associated with stress related diseases like
anxiety disorder, major depressive disorder, alcoholism and post-traumatic stress disorder
[35]. In particular GCs, secreted by the adrenal glands, like cortisol (CORT) and their effects
on hippocampal size will be discussed in the following sections.
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4.1 Organizational Effects of Hormones Secreted at the HPA Axis
While it is known that GC receptors (GRs) are expressed in rat brains around embryonic
days 13 and 14, the timing of GR expression in humans is not exactly known [36]. However,
during the third week of pregnancy, the rat brain is at a similar state as the developing
human brain during the late first and early second trimester of pregnancy [37]. Since
psychological stress-induced secretion of CORT cannot be optimally attenuated during the
second trimester of pregnancy, women are more vulnerable to environmental stressors in
this phase [38]. Interestingly, during the late first and second trimester of pregnancy,
maternal environmental stressors (critical life events) increasing HPA activity are also
associated with an increased incidence of schizophrenia in the offspring [39]. Multiple
authors report that low birth weight, which is associated with hypercortisolism in the mother,
is linked to schizophrenia [40].
The idea that the action of hormones may underlie biological vulnerabilities in mental and
neurological diseases was discussed by Seckl and termed “foetal programming”. A large
part of foetal programming may be related to exposure to GCs or indirectly via environmental
stress [39]. In sheep, hypercortisolism in mothers, caused by environmental stress or under
nutrition, can lead to reduced brain weight at birth, delaying maturation of neurons,
myelination, glia and vasculature, to acute effects upon neuronal structure and synapse
formation and to a permanently altered brain structure. Prenatal hypercortisolism may also
affect the developing dopaminergic system, a notion which might be important for the
understanding of dopaminergic dysfunction commonly observed in schizophrenia and
psychosis. Finally, long-lasting changes in HPA functions programmed at birth might be
gender specific, a finding which would fit to the differences in the course of schizophrenia
between males and females [39].
In other studies, the severity of psychosis and the risk for conversion to Axis I psychotic
disorders in adolescent patients at high risk for schizophrenia were predictable by CORT
levels one and two years later [21,41]. Full-blown abnormalities in hormonal secretion and its
effects have been reported by a number of studies indicating a rise in baseline levels of
CORT and other stress hormones in medicated and drug-naïve adult schizophrenia patients
[42,43]. Further, support for GR abnormalities in established schizophrenia has been
provided by post-mortem studies of brains of schizophrenic patients. It has been observed
that GR messenger RNA expression was decreased in schizophrenia, a finding which was
explained by down regulation of receptors in response to chronic elevation of stress-
hormone levels throughout the lifespan in schizophrenia [44]. However, such post-mortem
findings also could have been distorted by the effects of antipsychotic medication, taken
during the course of life of the patients.
In summary, based on the above evidence, the second trimester of pregnancy in humans
can be considered as a time-window of increased sensitivity to maternal stress for the child.
The expression of GRs around the same time suggests that specifically GCs may be a
biological factor underlying the increased vulnerability to stress. In general, wide ranging
pathology in brains of schizophrenic patients may be attributable to pathology in GCs. This
pathology, including altered hippocampal volume, might be considered to be an
organizational effect of hormonal activity, which could be genetically predetermined.
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4.2 Glucocorticoids and hippocampal volume
The hippocampus is highly involved in the inhibition of the stress response at the HPA axis
[35] and binding of stress hormones on GRs at the level of the hippocampus may have
genomic (long lasting, organizational) and non-genomic (short-lasting, activational) effects
[35]. It has been suggested that GC secretion (also mediated by environmental stress) can
lead to changes in hippocampal volume, decrease in dendritic spine density and even cell-
death. These negative effects of stress on the brain and more specifically on the
hippocampus have been investigated in numerous animal studies [45]. It has been shown
that repeated doses of corticosterone or environmental stressors can cause thinning and
loss of pyramidal neurons in hippocampal area CA3 in vervet monkeys and rats. However,
these effects were observed to be reversible within 7-14 days after occurrence of the
stressor or corticosterone admission [46,47].  More recent studies in laboratory animals
indicate that after chronic stress GCs impair neurogenesis, induce atrophy of dendritic
processes and have a neurotoxic effect on the hippocampus [48].
With respect to humans, Cushing’s syndrome, a disease which is associated with increased
cortisol secretion as well as psychotic symptoms, has been found to be accompanied by
reversible bilateral decrease in hippocampal volume [48]. GCs are therefore assumed to be
plausible contributors to the atrophy in the hippocampus, particularly given that “the extent of
hypercortisolism predicts the extent of atrophy while the extent of recovery from
hypercortisolism predicts the extent of volume recovery” [48].
However, a critical review of the notion of the detrimental effects of GCs on the hippocampus
has clarified this issue in more detail. In this review the effect of GCs on distinct receptors is
assumed to influence cell birth, cell death and probably also cell differentiation. Activation of
GRs may lead to hippocampal cell death while activation of mineralocorticoid receptors
(MRs) may trigger neuroprotective mechanisms counteracting the cell death. MR occupation
appears to be essential for the survival of existing and newly generated neurons. Thus, this
duality of receptor types is important for hippocampal cell fate, GR being a promoter of cell
death and MR a mediator of cell survival. More specifically, it is assumed that activation of
GR can induce loss of neurons in the absence of MR activation while usually the effects only
involve dendritic atrophy and loss of synaptic contacts [49] Opposed to the findings showing
a negative association between hippocampal volume and basal cortisol levels, as reported
by Sapolsky [45,48], a study in healthy male volunteers did show that larger hippocampal
volume was associated with higher cortisol levels. In this study the cortisol response to
awakening (CRA) over four weeks and the cortisol response to a psychosocial stress task
was determined in healthy young (age range 19 – 32 years) males. It appeared that subjects
with larger hippocampal volumes showed a greater increase in cortisol in response to stress
and to awakening than subjects with smaller hippocampal volumes [50]. The authors
indicate that their measurement of reactive cortisol levels instead of diurnal cortisol levels
may lead to different results. In addition, they explain the results assuming that in a young,
healthy population both a pronounced cortisol response to stress and awakening; along with
a large hippocampus may be part of a healthy HPA system, reflecting a successful
adaptation to short-term stress.
Opposite to this finding in healthy young subjects, psychosocial and biological stress may
lead to a reduced volume of the hippocampus frequently observed in first psychosis
schizophrenic patients [47]. High levels of prenatal maternal stress are associated with
increased HPA activity being a high-risk factor for the development of schizophrenia in the
offspring later in life. Especially critical life events that may lead to an increase of stress
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hormone release, such as natural and man-made disasters, prenatal infections or death of a
loved one are associated with schizophrenia-like symptoms and anatomical changes in the
brain of the offspring [51-53].
Hippocampal size in patients at high risk for psychosis appears to be intermediate in volume
between that of healthy controls and diagnosed schizophrenic patients [54]. This finding
points to the possibility that hippocampal abnormalities are present early in the course of the
disease when full blown symptomatology is still absent [54]. Moreover, post-mortem studies
indicate a reduced hippocampal cell size and spine density in brains of schizophrenic
patients [55]. Thus, a hypersensitive hormonal stress system due to disinhibition of the HPA
axis may be a predisposition to the development of schizophrenia. As a consequence,
abnormal high levels of GCs during brain development may alter hippocampal volume and
functioning in subjects with a predisposition for schizophrenia.
4.3 Activational Effects of Hormones Secreted at the HPA Axis
As mentioned above, an environmental stressor could trigger schizophrenia-like symptoms if
a genetic predisposition for schizophrenia is present. Fluctuations in the secretion of
hormones as a response to an environmental stressor can be considered to reflect
maladaptive activational effects of hormones, which may be superimposed on the
organizational effects.
For example, in four schizophrenic patients, levels of urinary CORT were found to be
significantly higher (250%) immediately prior to psychotic episodes, when compared to
recovery periods [56]. Thus, intensity as well as frequency of psychotic symptoms in
schizophrenic patients appears to be related with long-term fluctuations in CORT [56]. Also
other studies have shown a direct relationship between increases in stress hormone levels
and the occurrence of psychosis. For instance, the occurrence of psychotic symptoms was
found to be associated with Cushing’s disease, a state of overproduction of CORT [12,57].
Case reports indicate that there is a remission of psychosis in Cushing's disease with the
correction of the hypercortisolemia [12,57]. Thus, by interfering with hormonal factors,
psychosis, a main feature of schizophrenia, could be prevented. This is convincing evidence
of the high potential of activational effects of stress hormones in the development of
psychotic symptoms, commonly observed in schizophrenia. Further, a recent review
reported that an enhanced stress response of the HPA axis as well as hypercortisolaemia
seem to be evident in subjects at an increased risk to develop schizophrenia-like symptoms
such as psychosis [58].
Especially pharmacological challenges such as the dexamethasone suppression test (DST)
are often used to investigate HPA axis dysfunction. Dexamemethasone (DEX) is an
exogenous gluccocorticoid agonist which leads to suppression of ACTH via the HPA axis
negative feedback loop. Thus, administration of DEX leads to suppression of cortisol and is
therefore also often used during the diagnosis of Cushing`s disease, as nonsupresssion of
cortisol after the administration of the DST is an index of HPA axis dysfunction. In patients
with schizophrenia and affective psychosis, higher post-DST levels of cortisol were reported
in comparison to healthy controls and depressed patients. Further, antipsychotic treatment
often reverses this response [59]. Moreover, schizophrenia patients which do not show a
cortisol suppression after administration of the DST had a higher variability on the Brief
Psychiatric Rating Scale and more unpredictable clinical outcome than patients showing
supression during the DST [60].
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Taken together, activational processes of hormones secreted at the HPA axis may play a
role in the onset of the symptomatology in schizophrenia. However, the evidence for
activational effects of stress hormones presented here are limited. First, most results are
discussed in regard to psychosis. Although it is a defining feature of schizophrenia, many
other mental diseases are associated with psychosis. Second, some of the findings indicate
that the levels of acute secretion and concentration of stress hormones in schizophrenia
might be relatively normal. Therefore, it may be assumed that the interaction of activational
effects with organizational effects of hormones, exemplified by hypersensibility of the HPA
axis, might explain these findings.
5. SOMATOTROPHIC AXIS
The somatotrophic, that is the growth hormone (GH)/ insulin-like growth factor-I (IGF-I)  axis
is involved in metabolism and the growth of body and brain due to the release and regulation
of growth hormone releasing hormone (GHRH), somatostatin (ST), growth hormone (GH),
and insulin-like growth factor I (IGF-I) [1]. GH and IGF-I have substantial effects on brain
development and body composition; abnormalities in the GH/IGF-I axis may lead to
developmental abnormalities [1], which may attribute to a biological vulnerability to
schizophrenia.
5.1 Organizational Effects of IGF-I
It has been hypothesized that IGF-I is involved in pre- and post-natal developmental
abnormalities in schizophrenia [61]. This is based on the notion that low serum IGF-I levels
are related to low birth weight and low IQ in childhood, while low birth weight and low IQ both
appear to be related with increased risk of schizophrenia [40]. In a study in antipsychotic-
naïve schizophrenia patient’s plasma levels of glucose, insulin, IGF-I and cortisol were
compared to those of healthy control subjects [62]. The finding that the mean plasma IGF-I
level was significantly lower in patients supports the IGF-I deficiency hypothesis as an
interpretation of the etiology of schizophrenia. A recent study found a 2-fold decreased
serum concentration of GH in a cohort of 236 first and recent onset schizophrenia patients in
comparison to 230 matched controls. In addition, GH content was decreased by
approximately 1.5 fold in post-mortem pituitaries from schizophrenic subjects (n = 14)
compared to controls (n = 15) [63]. IGF-I levels were not determined in this study. It may be
suggested that lower activity of the somatrotrophic axis might render the brain more
sensitive to neurodevelopmental damage potentially leading to schizophrenia. Since IGF-I
receptors are concentrated in the hippocampus, this brain region is likely to be affected due
to IGF-I deficits in addition to the detrimental effects of GCs. Moreover, cortisol and IGF-I
have been found to be reciprocally related, which became evident in a longitudinal study in
schizophrenic patients examining the effect of antipsychotic treatment on IGF-I and cortisol.
Following antipsychotic treatment, cortisol levels decreased and IGF-I levels increased. The
larger the reduction in cortisol level, the larger the increase in IGF-I level and the larger the
improvement in positive symptoms [64]. It may well be true that hypercortisolemia can result
in decreased IGF-I levels and that effects of hypercortisolemia on the pathogenesis of
schizophrenia might partially be mediated by its inhibitory effects on IGF-I secretion. In turn,
decreasing the cortisol levels by antipsychotics might result in significant elevation of IGF-I in
schizophrenic patients.
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Thus, subnormal IGF-I levels may be a predisposition to the development of schizophrenia.
In addition, low levels of IGF-I during brain development may alter hippocampal functioning
in subjects with a predisposition for schizophrenia.
6. THE ROLE OF EPIGENETICS IN THE DEVELOPMENT OF SCHIZOPHRENIA
As is clear from the paragraphs above, it has been generally accepted that both genetic and
environmental factors (affecting hormonal levels) play a significant role in the pathogenesis
of schizophrenia. In some cases, genetic factors alone can be responsible for the
development of schizophrenia, while in other cases environmental factors also attribute to
the unfolding of the neuropathology.
As environmental factors may rarely being sufficient to cause schizophrenia independently,
they are assumed to interact with the underlying genetic liability. However, the pattern of
interaction between environmental and genetic factors is still poorly understood. Recent
advances in epigenomics have increased the knowledge of this interaction by identifying
molecular mechanisms that mediate environmental influences on gene expression and
activity, epigenetics being defined as changes in gene expression that occur without
changes in DNA sequence [65]. Two of the most widely studied epigenetic changes are DNA
methylation and histone modifications [66]. The prenatal erasure and programming of DNA
methylation patterns makes the in utero time period a window of potential vulnerability for
epigenetic dysregulation from environmental exposures, which may be particularly relevant
in endocrinology [67]. Another potential vulnerable window for epigenetic dysregulation that
might affect endocrine systems include puberty, during which time there is an overall rapid
increase in DNA turnover and cell growth [68].
Particularly during embryogenesis genes may epigenetically marked, that mean activated or
silenced when epigenetic instructions for ontogenetic development are set in place but also
later in life in response to environmental influences [69]. There is increasing evidence that
epigenetic mechanisms play a crucial role in mediating the lasting effects of maternal care,
stress hormones and nutrition on hippocampal structure and function. For instance, animal
studies indicated that early maternal care modulates gene expression resulting in stable
patterns of GR expression in the hippocampus and a variable vulnerability to stress in adult
offspring [70]. With respect to humans, subjects with histories of abuse manifest increased
methylation and decreased expression of hippocampal GRs and long-term vulnerability to
stress [71]. Thus, long lasting effects of fetal exposure to hormones like CORT and the
availability of nutrients on hippocampal development may be mediated by epigenetic
mechanisms [72].
With respect to schizophrenia, prenatal factors that are associated with increased risk of
schizophrenia are viral infections, maternal stress and depression, hypoxia and nutritional
deficiencies. Postnatal factors, extending from early postnatal period to late adolescence
and later include social pathogens like urbanicity, psychological pathogens like stress and
chemical pathogens like cannabis use. These prenatal and postnatal factors may increase
the risk of schizophrenia by epigenetic misregulation of the liable genome [73]. These
epigenetic mechanisms may also mediate the hormonal impact on the development of
schizophrenia. When comparing the hormone action within the developing versus the adult
brain, it may be true that hormonal exposure during brain development can create lasting
epigenetic modifications while hormone exposure in adulthood can have more transient
effects on gene expression. However, increasing knowledge of the epigenetic regulation of
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neuroendocrine systems suggests that effects of epigenetic modifications are more complex
[74].
The current knowledge of epigenetic modulation suggests that prenatal exposure to
abnormal levels of cortisol has lasting effects on hippocampal structure and increases the
risk of schizophrenia by the mediation of epigenetic mechanisms.
7. HORMONAL TREATMENT IN SCHIZOPHRENIA
In recent years an interrelationship between steroid hormones and dopamine secretion has
been shown, suggesting that treatment with hormonal agents may be beneficial in
schizophrenia [22,23,75,76]. Traditionally, most of the hypotheses regarding the etiology of
schizophrenia are based on dopaminergic abnormalities. Recently, also glutamate and
serotonin have been accepted to be involved in the pathophysiology of the disease. As E
influences dopaminergic, glutamatergic and serotonergic neurotransmission, its action might
influence several neurochemical pathways important in the disease and may have effects
similar to atypical antipsychotics [22,23].
Indeed, there is growing evidence that adjunctive therapy with E might play a role in the
treatment in schizophrenia, as it might counteract some of the side-effects (like sexual
dysfunction) of antipsychotics while having independent properties similar to antipsychotic
medication.
In one recent study, 102 women with a psychotic illness were treated by adjunctive
treatment with estradiol (100 μg E per day for 28 days). This treatment led to significant
improvement in total PANSS scores, positive symptoms, general psychopathology and
cognition compared to antipsychotic medication alone [22,23]. E has also been
administrated to 14 women with postpartum psychosis, while the Brief Psychiatric Rating
Scale (BPRS) was used to evaluate the change of symptoms over time. The psychotic
symptoms were reported to decrease within 2 weeks of E treatment. In two patients who
discontinued the E treatment, relapse of psychotic symptoms was observed within 2 weeks
[63]. Although postpartum psychosis shares main features with schizophrenia, it cannot be
considered to be the same disease. Still, it is likely that similar mechanisms attribute to
psychosis in postpartum psychosis, as the disease shows high comorbidity with other
neuropsychiatric conditions. Currently the antipsychotic effects of E in schizophrenic woman
as well as improvement of the neuropsychological performance in response to E treatment
have been accepted by many scientists [22,23].
However, it is important to note that treatment with E can be restricted by severe adverse
effects, such as breast and uterine change, which may ultimately lead to breast and uterine
cancer [77,78]. These kinds of side effects seem to be reduced in patients treated by the
highly selective E receptor modulator raloxifene. As this pharmacological agent has E
receptor agonist effects in the brain but antagonist effects in breast tissue the risk for the
development of uterine cancer is reduced in comparison to patients treated with other E
agents. [77].
Recently, the antipsychotic effects of raloxifene as adjunctive treatment to antipsychotic
medication were studies in postmenopausal schizophrenic women. The administration of
120 mg raloxifene leads to a significantly more rapid recovery of total and general psychotic
symptoms than the administration of antipsychotic medication in combination with a placebo
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[77]. Further, significantly greater improvement in total PANSS scores and general
psychopathology PANSS scores in comparison to placebo were observed in
postmenopausal psychotic women after 12 weeks of 120 mg daily oral raloxifene.
Comparable results have been found in other studies [22,23]. Thus, raloxifene seems to
show high potential as adjunctive treatment in daily clinical practice.
With respect to the treatment of schizophrenia in men, feminizing effects of E in men may be
a reason for restricting treatment. However, the administration of estradiol doses below
2.5mg per day for less than 4 weeks has been found not to induce such side effects in men
[79,80,81]. Thus, E has been used as adjunctive treatment in males. For instance, in a
placebo-controlled trial in 50 men diagnosed with schizophrenia, 2mg oral estradiol was
administrated as an adjunctive treatment to atypical antipsychotics. Participants receiving
the estradiol showed a more rapid decline in general psychopathology, which was attributed
to increased levels of serum estradiol, as well as to decreased FSH and testosterone. As
28% of the patients receiving treatment did not achieve an increase in serum estradiol, the
authors propose further studies in schizophrenic men regarding type, dose and
administration route of E [82]. In another recent study, 53 schizophrenic men were
adjunctively treated with either 2mg oral E or placebo in a two-week randomized controlled
trial. The E group displayed a significantly faster improvement in general psychopathology
than the placebo group, and notably, no increase in adverse side-effects were observed
[22,23].
Also T has been proposed as adjunctive treatment in schizophrenic men. A randomized,
placebo controlled trial in 30 schizophrenic men using 5g of 1% testosterone gel daily
additionally to antipsychotic medication lead to an improvement in negative symptoms in
patients treated with T as compared to patients treated with a placebo [34].
With respect to steroid hormones, GR antagonists like mifepristone have been hypothesized
to have positive effects on symptomatology in schizophrenia. This notion is based on the
frequently observed abnormally high levels of GRs and GC concentrations in schizophrenic
patients [83]. However, positive effects of treatment with mifepristone in schizophrenia have
not been found, suggesting that such treatment might be more beneficial in schizophrenic
patients with demonstrable HPA-axis dysfunction than in patients without such abnormalities
[83]. Further, as doses were relatively low, studies administrating higher doses are
warranted [84]. Treatment of schizophrenic and schizoaffective disorder with the
antiglucocorticoid ketoconazole led to reductions in depression but not in psychotic
symptoms [85].
In general, as harmful organizational effects of hormones may induce a stable abnormal
biological state, short-term hormonal treatment cannot be expected to reduce symptoms of
schizophrenia in the long-term. As a consequence, treatment starting early in life may be
needed to positively affect organizational processes in the brain, thereby reducing the
biological vulnerability to schizophrenia. Such an approach may be exemplified by treatment
with GR antagonists during childhood, after GC/GR vulnerability has been diagnosed in the
child. However it should be noted that interacting with the hormonal system early in life may
have severe maladaptive developmental effects. Nonetheless, it seems important to further
increase our knowledge of hormonal drugs that selectively interact with the hormonal system
in people in the prodromal phase or early phase of schizophrenia. Eventually with the use of
such hormone medication a reduction or even reverse of the biological vulnerability to
schizophrenia may be accomplished during the development of the brain.
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8. CONCLUSIONS
The present review discusses the available evidence of the involvement of a variety of
hormonal factors in the onset and development of schizophrenia. Environmental stressors
and genetic predispositions may induce abnormal hormonal processes in the brain of the
offspring during pregnancy and adolescence. We believe that genetic predispositions may
lead to developmental hormonal abnormalities early in life resulting in an increased risk to
develop schizophrenia later in life when strong hormonal changes are present. Further, such
abnormalities might independently or in combination with stressful events already be
exacerbated during pregnancy and in childhood. These early induced vulnerabilities may
represent a causality for schizophrenia as they eventually may lead to an abnormal
hormonal regulation, the development of sensitization or resistance of receptors and
ultimately to a biological vulnerability to schizophrenia. The long life genetic susceptibility to
hormonal influences may be mediated by epigenetic mechanisms. Further, abnormal
hormonal processes may damage brain structures and neurons. We further believe that
factors causing hormonal abnormalities, such as prenatal maternal stress or genetic
predispositions may later in life result in general neurochemical unbalance, as observed in
the hormonal and neurochemical abnormalities in schizophrenia and associated psychosis.
In puberty when hormonal levels start to show substantial alterations, the responses of the
hormonal system may be disturbed due to the formerly induced developmental
abnormalities. As a consequence of the abnormal hormonal responses, structural and
functional changes in the pituitary gland and the hippocampus may occur. Disturbance of the
hormonal system and structural alterations of the pituitary gland and the hippocampus may
be superimposed by phasic hormonal fluctuations that may ultimately trigger the symptoms
of schizophrenia. Thus, sub-threshold abnormalities of hormonal levels and receptors may
be present in the prodromal phase of schizophrenia and prior to the onset of the first
psychosis.
As schizophrenia follows a different course in men and women distinctive hormonal
processes in male and females might play a role in the development of schizophrenia.
Differences in these developmental processes are mainly observed in relation to gonadal
hormones, which are known to play an important role in gender-specific development. It is
very likely that these hormones are also related to the gender-specific symptomatology,
epidemiology and time-course of the disease.
Since the development of schizophrenia seems to be associated with hormonal changes in
pregnancy and puberty, hormones of the HPG axis are the most likely candidates for being
the mediators of the maladaptive brain development in schizophrenia. In addition, stress-
hormone secretion at the HPA axis could be an additional factor to trigger the onset of
schizophrenia and psychosis. A very important contribution to the knowledge of the
mechanisms especially involved in organizational effects of hormones on brain development
can be provided by studies on the epigenetic regulation of neuroendocrine systems. Current
evidence indicates that prenatal exposure to abnormal levels of cortisol can permanently
change hippocampal structure and might increase the risk of schizophrenia by the mediation
of epigenetic mechanisms. Insight in these epigenetic mechanisms explaining lifelong
genetic susceptibility to hormonal influences may provide new treatment strategies.
Altogether, it seems worthwhile to study hormonal abnormalities in schizophrenia, especially
in terms of their neuroactive properties and epigenetic modulators. Research on abnormal
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hormonal factors in schizophrenia may lead to alternative treatment approaches and may
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